Our Mission

Resolving biology
to advance human health

10x Genomics builds products to interrogate, understand and master biology to advance human health.

Our products have been adopted by researchers around the world, including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 700 research papers on discoveries across the life sciences, including oncology, immunology, and neuroscience.

Our Team

Executive Management

thumbnail Serge Saxonov Chief Executive Officer, Co-founder
thumbnail Brad Crutchfield Chief Commercial Officer
thumbnail Ben Hindson Chief Scientific Officer, President, Co-founder
thumbnail Justin McAnear Chief Financial Officer
thumbnail Jamie Osborn Vice President, Finance
thumbnail Jean Philibert Chief People Officer
thumbnail Sam Ropp Senior Vice President, Global Sales
thumbnail Jonathan Schimmel Vice President, Global Support and Sales Operations
thumbnail Michael Schnall-Levin Senior Vice President, R&D, Founding Scientist
thumbnail Eric Whitaker General Counsel
thumbnail Alexander Wong Senior Vice President, Product, Software & Infrastructure
thumbnail Paul Wyatt Vice President, Operations

Board Members

Serge Saxonov Chief Executive Officer, Co-founder

Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. He defined vision and strategy, contributed to core inventions, and led the company through multiple phases of rapid growth. In 2016, he was honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Prior to 10x Genomics, Serge was VP of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was Founding Architect and Director of R&D at 23andMe. There he defined the initial conception of the product, built many elements of the technology, and drove strategy and execution of R&D functions as the company scaled. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.

Shehnaaz Suliman Board of Directors
Shehnaaz Suliman, M.D., M.Phil., M.B.A. has served on our board or directors since August 2019. Dr. Suliman is a strategic dealmaker focused on driving exceptional value for patients and investors through acquisitions and licensing transactions. Dr. Suliman serves on the board of directors for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and has served on the Board of Parvus Therapeutics. Dr. Suliman was previously Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc., a position she held since July 2017. Prior to her position at Theravance, Dr. Suliman worked for Genentech, Inc. as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group from September 2010 to May 2015 and as Vice President and Global Therapeutic Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc. between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and a boutique advisory firm advising public and private companies on buy- and sell-side transactions. Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.
Ben Hindson Chief Scientific Officer, President, Co-founder
Ben Hindson has served as Chief Scientific Officer and Director of 10x Genomics since its founding in 2012. Prior to 10x Genomics, Hindson was Co-founder and Chief Scientific Officer of Quantalife, a privately-held life sciences company that developed and commercialized a droplet digital PCR platform, until its sale to Bio-Rad in 2011. From 2002 to 2008, he served in various positions of increasing responsibility at Lawrence Livermore National Laboratory, in the Chemical and Biological Weapons Non-proliferation Program. He has published extensively in his field and holds many patents for assays and instrumentation. Hindson earned his BSc in Chemistry in 1998 and his PhD in Chemistry in 2001 from Deakin University, Australia.
Sri Kosaraju Board of Directors

Sri Kosaraju has been a Board member of 10x Genomics since March 2019. He currently serves as President of Penumbra (NYSE: PEN), a global healthcare company focused on innovative therapies. Mr. Kosaraju joined Penumbra in 2015, serving as CFO and Head of Strategy until his promotion to President in 2019. Prior to joining Penumbra, he had over 16 years of experience in investment banking. Mr. Kosaraju worked for J.P. Morgan Securities LLC (J.P. Morgan) from 1999 until 2015, where he held a variety of positions, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Mr. Kosaraju received a B.S in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).

Mathai Mammen Board of Directors

Dr. Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.

Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.

Prior to Merck, Dr. Mammen led R&D at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products (Breo®, Anoro®, Vibativ®), two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

Bryan Roberts Board of Directors
Bryan Roberts, Ph.D. has served on the Board of Directors since November of 2013. Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD), and Kyruus and also serves on the Board of several other companies, including 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq (NASDAQ: ZLTQ). Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN), and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, 2008 – 2014. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
John Stuelpnagel Chairman
John Stuelpnagel has been Chairman of 10x Genomics since August of 2013. In addition, John co-founded and was Executive Chairman of Ariosa from 2010 to 2015 when the company was acquired by Roche. He was also the Chairman of Sequenta from 2010 to 2015 when that company was merged with Adaptive Biotechnologies where he continues as a Member of the Board. Previously, John co-founded Illumina, Inc. and was instrumental in making Illumina one of the most successful life science companies. During his 12 years at Illumina, John served as the company’s first CEO and most recently served as COO. Prior to Illumina, John was a venture capitalist at CW Group. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
US Locations

Pleasanton, CA

10x Genomics
6230 Stoneridge Mall Road
Pleasanton, CA 94588-3260
+1 925 401 7300
+1 800 709 1208

San Francisco, CA

10x Genomics
160 Spear St.,
Suite 1130
San Francisco, CA 94105
+1 925 401 7300
+1 800 709 1208
EU Locations

Leiden, The Netherlands

10x Genomics B.V.
Crown Business Center Key Point II,
Schipholweg 103,
2316 XC Leiden,
The Netherlands

Stockholm, Sweden

Spatial Transcriptomics,
Part of 10x Genomics, Inc
Södra Fiskartorpsvägen 15C,
114 33 Stockholm,
Sweden
ASIA Locations

Singapore

10x Genomics Pte Ltd
Science Park 2,
20 Science Park Road,
#02-32A/33 Teletech Park,
Singapore 117674

Shanghai, China

10x Genomics (Shanghai) Co., Ltd
2421, Cloud 9 International Plaza,
No 1018 Changning Road,
Shanghai, 200042 China

Distributors

Join our expanding network of global distributors!

We invite interested distributors to email info@10xgenomics.com.

Select a region below to find a distributor in your area.

We’re here to help.

Contact Us